Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Pharmacology > Opiod Analgesics and Antagonists > Flashcards

Opiod Analgesics and Antagonists Flashcards

1
Q

Opioids - MoA

A

Activation of opioid receptors leads to inhibition of adenylyl cyclase, and a decrease in the concentration of cyclic adenosine monophosphate, an increase in K+ conductance and a decrease in Ca2+ conductance.
The activated Gai subunit of the G protein directly inhibits the adenylate cyclase enzyme, and the Gbetagamma subunits are thought to mediate the changes at the Ca and K channels. These actions cause both presynaptic inhibition of neurotransmitter release from the central terminations of small diameter primary afferent fibers and postsynaptic inhibition of membrane depolarization of dorsal horn nociceptive neurons.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Opioid agonists - Effects

A

CNS: Analgesia, sedation, euphoria or dysphoria, miosis, respiratory depression and inhibition of coughing reflex, nausea and vomiting

Analgesia: produced by activation of opioid receptor in the spinal cord and at several supraspinal levels.
Sedation and euphoria due to effects on midbrain dopaminergic, serotonergic and noradrenergic nuclei.
Miosis (constricted pupils): produced by the direct stimulation of the Edinger Westphal nucleus of the oculomotor nerve –> parasymp stimulation of iris sphincter muscle.

Cardiovascular: Vasodilation (caused by histamine release from mast cells in peripheral tissues), Orthostatic hypotension (decreased peripheral resistance and reduction in baroreceptor reflex activity). Pt w CAD the decreased peripheral resistance –> reduction of cardiac work and myocardial oxygen demand.

GI, Biliary and Genitourinary system: Constipation (increased intestinal smooth muscle tone), increased biliary sphincter tone and pressure –> exacerbation of pain in patients with biliary dysfunction or gallbladder attack.

Genitourinary: increased bladder sphincter tone, prolongation of labor, urinary retention
Neuroendocrine: inh of LH release. Stimulation of release of ADH and prolactin.
Immune system: Suppress the activity of some lymphocytes, incl natural killer cells –> high rate of infectious diseases in heroin addicts.
Dermal: flushing, pruritus, urticaria

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Opioids - Adverse effects

A

Respiratory depression
Decreased Hypercapnic drive (stimulation of resp centers by increased CO2 levels) + little effect of hypoxic drive
Decreased Respiratory tidal volume and rate –> rate falls to 3-4 pr min after overdose
Increased intracranial pressure due to increased cerebral blood flow
Nausea and vomiting by stimulating the chemoreceptor trigger zone in medulla
Itching/pruritus, flushing reaction (histamine release by mast cells)
Allergic reactions

Tolerance: decrease in initial pharm effect observes after chronic or long-term adm. Results from down-regulation of opioid receptors. Not developed to miosis and constipation. Considerable tolerance to resp depp. Accompanied by physical dependence
Cross tolerance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Opioids - Contraindication and antidote

A

Closed-head injury

Naloxone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Strong opioid agonists

A 
Morphine
Fentanyl 
Sufentanil 
Alfentanil 
Remifentanil 
Meperidine 
Methadone 
Oxycodone
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Which strong opioid agonists have some effect on Kabba receptor?

A

Morphine and Sufentanil

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Morphine - Clinical use

A

Severe pain associated with trauma, MI and cancer.

MI: relieves pain and anxiety + dilating coronary arteries and decrease myocardial oxygen demand.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Which drugs is the diacetic acid ester of morphine?

A

Heroin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Metabolites of Morphine

A

Principle metabolite: 3-glucuronide (inactive)

6-glucuronide is more active than morphine + longer half-life. It contributes to analgesic effectiveness of morphine.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Most potent opioid agonists

A

Fentanyl
Sufentanil
Alfentanil
Remifentanil

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Sufentanil - MoA

A

Strong mu receptor agonist. Some effect on kabba and delta receptors.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Fentanyl - Clinical use

A

Long-acting transdermal skin patch: Continuous pain relief for pt with severe or chronic pain
Mucosal, buccal and nasal spray: Breakthrough pain
Parenteral: preop and postop + adjunct to general anesthesia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Fentanyl - Adverse effects

A

Produces less nausea and vomiting.

Truncal rigidity when used as an adjunct to parenteral anesthesia.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Alfentanil - Clinical use

A

Part of anesthesia procedures

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Remifentanil - Clinical use

A

Short term procedures and outpatient surgery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Meperidine - Clinical use

A

DOC for pain ass w labor and pt w biliary dysfunction or gallbladder attack because it has less pronounced action of smooth muscle.
Analgesia for obstetric or postsurgical analgesic.
Oral: moderate to severe pain in outpatient setting
Short-term: acute pain syndromes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Meperidine - Adverse effects

A 
Less constipation (Less pronounced effect on GI, biliary and uterine smooth muscle --> less likely to cause constipation or increased biliary pressure)
High doses --> converted to toxic metabolite normeperide -->CNS excitation, convulsions and tremors.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Methadone - Clinical use

A

Ambulatory patients to treat opioid dependence (methadone maintenance program) or chronic pain.
Opioid-dependent pt: prevent craving for heroin or other opioids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Oxycodone - MoA

A

Strong mu receptor agonist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Oxycodone - Clinical use

A

Moderate or severe pain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Oxycodone - Adverse effects

A

Incidence of death (Only crushproof tablet available)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Moderate opioid agonist

A

Codeine
Hydrocodone
Propoxyphene

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Moderate opioid agonists - MoA

A

Are less potent than the strong opioid agonists. Because they do not produce maximal analgesia at doses that are well tolerated by patient, they are used in submaximal doses, and almost always combined with an NSAID analgesic.

24
Q

Codeine - MoA

A

Converted to morphine by CYT P450 isozyme CYP2D6

3-O-methyl derivative of morphine

25
Q

Codeine, Hydrocone and Propoxyphene - Clinical use

A

Mild to moderate pain
Antitussive effect
Propoxyphene have half the analgesic effect of codeine –> more antitussive effect

26
Q

Codeine - Contraindication

A

pregnant and nursing mothers who are ultrarapid metabolizers of codeine have a risk of lethal morphine exposure to the fetus or nursing infant.
Persons with deficient variations of CYP2D6 obtain little pain relief.

27
Q

Codeine - Adverse effects

A

Constipation

28
Q

Propoxyphene - MoA and Adverse effects

A

Chemical analogue of methadone

Cardiac abnormalities

29
Q

Other opioid agonists

A 
Tramadol
Tapentadol 
Dextrometorphan 
Diphenoxylate 
Loperamide 
Eluxadoline
30
Q

Tramadol - MoA

A

Agonist at mu-opioid receptors and inhibited the neuronal reuptake of serotonin and norepinephrine. Reuptake inh may potentiate the inhibitory effects of serotonin and norepinephrine on pain transmission in the spinal cord.

31
Q

Tramadol - Clinical use

A

Moderate pain

Chronic pain syndrome

32
Q

Tramadol - Adverse effects

A

Produce minimal cardiovascular and respiratory depression.
The drug lowers seizure threshold and the risk of seizures is increased when used with antidepressants.
Increased risk of suicidal thought and behavior

33
Q

Tapentadol - MoA and Clinical use

A

Agonist at mu-opioid receptors and reuptake transporters, but inhibits only norepinephrine reuptake

Moderate pain

34
Q

Dextrometorphan - MoA

A

Nonselective serotonin reuptake inhibitor
Sigma-1 receptor agonist
NMDA antagonist

35
Q

Dextrometorphan - Clinical use

A 
Cough
Pseudobulbar affect (emotional lability) in comb w quinidine
36
Q

Diphenoxylate

Loperamide - MoA and Clinical use

A

Activate opioid receptors in gastrointestinal smooth muscle

Diarrhea

37
Q

Eluxadoline - MoA and Clinical use

A

Agonist at mu and kappa opioid receptors and antagonist at delta opioid receptors.
Activation of mu receptors leads to decreased intestinal motility and relief of diarrhea, whereas actions of eluxadoline on other opioid receptors reduces the incidence of constipation caused by mu opioid agonists.

IBS with diarrhea

38
Q

Mixed opioid agonist-antagonist and partial agonists

A

Buprenorphine
Butorphanol
Nalbuphine
Pentazocine

39
Q

Mixed opioid agonist-antagonist and partial agonists - MoA

A

Partial agonist or antagonist at mu-opioid receptors and show agonist or antagonist at kappa-receptors.

40
Q

Mixed opioid agonist-antagonist and partial agonists - Clinical use

A

Parentally: preoperative and postoperative analgesia, obstetric analgesia during labor and delivery.

Orally/nasally: moderate to severe pain

41
Q

Mixed opioid agonist-antagonist and partial agonists - Adverse effects

A

Less respiratory depression as the doses are increased
Lower liability for drug dependence and abuse.
Can cause anxiety, nightmare, psychotomimetic effect; hallucinations (result of activation of kappa-receptors), precipitate withdrawal in a person physically dependent on full opioid agonist.
Less constipation

42
Q

Buprenorphine - MoA

A

Partial agonist at mu-opioid receptor and has slow dissociation from the receptor after binding –> therefor somewhat longer acting then other opioids.

43
Q

Buprenorphine - Clinical use

A

Outpatient treatment of opioid dependence.

44
Q

Butorphanol

Nalbuphine - MoA

A

kappa-receptor agonist, have partial agonist or antagonist activity at mu-opioid receptors.

45
Q

Butorphanol

Nalbuphine - Clinical use

A

Relieve pain during child birth

46
Q

Pentazocine - MoA

A

kappa-receptor agonist with additional activity at (sigma) receptors, a class of receptors mediating the psychotomimetic effect of PCP and Ketamine.

47
Q

Pentazocine - Clinical use

A

Parenteral: preanesthetic medication and supplement to surgical anesthesia.
Oral: moderate to severe pain

48
Q

Pentazocine - Adverse effect

A

Parenteral use of an oral formulation: Severe cardiovascular effect, especially in patients with existing cardiovascular disease.
Causes hallucinations.

49
Q

Opioid antagonists

A

Naloxone
Natrexone
Naloxegol
Methylnaltrexone bromide

50
Q

Naloxone and Naltrexone - MoA

A

Competitive opioid receptor antagonist and can rapidly reverse the effects of morphine and other opioid agonists. They are chemical analogues of morphine, with bulky chemical groups attached to the morphine molecule. This modification allows the molecule to bind to the opioid receptor but prevents the confirmation change in the receptor required for agonist activity.

51
Q

Naloxone - Clinical use

A

Opioid overdose- given IV
Alcohol and opioid dependence
Decrease opioid-induced constipation
Comb with opioid agonist in oral formulation to prevent crushing of the pill and IV abuse.
Opioid maintenance therapy comb w buprenorphine

52
Q

Naloxone - Adverse effects

A

If given IV: block opioid effects and withdrawal effect

53
Q

Naltrexone - Clinical use

A

Alcohol and opioid dependence

54
Q

Naloxegol - MoA

A

PEGylated naloxone. Pegylation increases drug solubility and improves pharmacokinetic profile.
Opioid analgesics inh GI motility, Naloxegol binds to GI opioid receptors and block the opioid-induced constipation.

55
Q

Naloxegol

Methylnaltrexone bromide - Clinical use

A

Relief of opioid-induced constipation

56
Q

Methylnaltrexone bromide - MoA

A

Its ability to block opioid binding in peripheral tissues decreases opioid-constipation effects.

Pharmacology (55 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions